The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2024 | Overview of therapeutic targets of interest in the treatment of mesothelioma
Dean Fennell, FRCP, PhD, University of Leicester, Leicester, UK, discusses some therapeutic targets of interest in the treatment of mesothelioma. An ongoing trial is using TEAD inhibitors to target the transcriptional oncogenic TEAD pathway, often activated in response to inhibitory mutations of the NF2 pathway. This showed promise with some responding patients. In an upcoming clinical trial, Prof. Fennell is also aiming to target MDM2 in 9p21 mutated mesothelioma. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria – AstraZeneca; Bayer; Boehringer Ingelheim; Boehringer Ingelheim; Bristol Myers Squibb; RS Oncology (Inst)
Consulting or Advisory Role – Bristol-Myers Squibb; RS Oncology
Speakers’ Bureau – BMS; Boehringer Ingelheim
Research Funding – Astex Pharmaceuticals (Inst); Bayer (Inst); BerGenBio (Inst); Boehringer Ingelheim (Inst); Bristol Myers Squibb (Inst); Clovis Oncology (Inst); GlaxoSmithKline (Inst); Iovance Biotherapeutics (Inst); MSD Oncology (Inst); Owkin (Inst); Roche UK (Inst); RS Oncology (Inst)
Travel, Accommodations, Expenses – Bristol-Myers Squibb; Janssen Oncology; RS Oncology
